Navigation Links
CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
Date:1/6/2017

LA JOLLA, Calif., Jan. 6, 2017 /PRNewswire/ -- Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis.

Acute pancreatitis, sudden painful inflammation of the pancreas, is typically a mild disorder, but can be very serious.  In severe cases it can lead to organ failure and sepsis, where extended hospital stays, time in the ICU and substantial morbidity and even mortality are seen. Acute pancreatitis has many different causes, ranging from alcohol and gall stones, which are responsible for the majority of cases, to drug reactions, viral infections or local cancers; there are also hereditary forms.  At this time there are no disease-modifying therapies available; patients receive supportive care, including fluids and pain medication.

Michael Dunn, President of CalciMedica, said, "We are very excited that CM4620 has advanced to human studies.  Acute pancreatitis is a disease with significant unmet medical need, especially its more severe form.  Our preclinical work and that of others strongly indicates that excess calcium in pancreatic cells is a key player in this disease.  We believe that CM4620 can help to modify the disease process and benefit patients, and hope to progress from these safety studies to testing in patients by the end of this year."

About CRAC channels and Orai

CRAC channels, comprising Orai and regulatory STIM proteins, function to maintain proper levels of calcium in most non-excitable cells.  In immune cells, particularly T cells, calcium is an important intracellular signaling molecule that controls cytokine production and the immune response.  In T cells CRAC channels are the primary means by which intracellular calcium levels are modulated.  In addition, aberrant activation of CRAC channels in pancreatic acinar cells is thought to play a key role in the pathobiology of acute pancreatitis.

About CalciMedica, Inc.

CalciMedica is the leading biopharmaceutical company focused on CRAC channel drug discovery and development, seeking novel drugs for the treatment of acute or chronic diseases in which inflammation plays a role. For example, CRAC channels control calcium entry that is essential for the adaptive immune response, and this pathway has been clinically validated as an important drug target in humans through the use of calcineurin inhibitors that act downstream from CRAC channels. For more information, please visit the company website at www.calcimedica.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/calcimedica-initiates-phase-1-clinical-studies-for-crac-channel-inhibitor-300386948.html


'/>"/>
SOURCE CalciMedica, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform
2. China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species
3. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
4. Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism
5. NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
6. Rolapitant reduces nausea and vomiting in Phase III trial
7. NIH funds next phase of Tissue Chip for Drug Screening program
8. Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN
9. New simple setup for X-ray phase contrast
10. More than just a hill of beans: Phaseolus genome lends insights into nitrogen fixation
11. ASU embarks on $9 million next phase of an effort to assess an absorbed radiation dose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2018)... (PRWEB) , ... October 11, 2018 , ... ODSC Europe ... saw a 100% increase in attendance at the event from September 19-22. , ... and artificial intelligence sessions across 10 tracks and 4 days. Attendees were given key ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... and collaboration solutions, was present at Microsoft Ignite 2018, in Orlando, Florida, when ... , Microsoft issued a statement about the new direction of Skype for Business ...
(Date:10/5/2018)... ... October 04, 2018 , ... Nothing brings a team together like cooking ... , Cooking appeals to companies because it encourages a range of healthy ... and decision-making skills. It’s also appealing in that everyone – no matter their ...
Breaking Biology News(10 mins):
(Date:9/28/2018)... ... 2018 , ... GlycoMark®, Inc. has announced a partnership with ... the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions ... GlycoMark test to its network of physicians through its sales organization and MD ...
(Date:9/27/2018)... , ... September 26, 2018 , ... ... are way ahead of their primary care physicians, according to a new Zeldis ... study, patients and doctors were asked about consumer adoption of fitness and health ...
(Date:9/27/2018)... ... 2018 , ... This past weekend at the TB Innovation ... announced they will formally merge companies and integrate their technologies to create a ... diseases. These two social enterprise corporations, both of which focus heavily on medication ...
(Date:9/22/2018)... ... September 20, 2018 , ... ... a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform ... biomarker profiling to empower clinical trials in the immuno-oncology (IO) space. , ...
Breaking Biology Technology: